AES CORP. DL-,01/ US00130H1059 /
2024-05-22 9:31:07 PM | Chg. +0.080 | Volume | Bid10:00:02 PM | Ask10:00:02 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
19.380EUR | +0.41% | 716 Turnover: 13,877.760 |
19.276Bid Size: 290 | 19.398Ask Size: 290 | 13.74 bill.EUR | - | - |
GlobeNewswire
05-21
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients w...
GlobeNewswire
05-21
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Poten...
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National ...
GlobeNewswire
05-15
Andes, HiRain, and HPMicro Join Hands to Build RISC-V AUTOSAR Software Ecosystem
GlobeNewswire
05-15
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT...
GlobeNewswire
05-13
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Tre...
GlobeNewswire
05-13
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
GlobeNewswire
05-09
PRP Group Launches Anonymous Edvisors Platform to Facilitate Feedback Sessions Between Administrator...
GlobeNewswire
05-06
Inmagene Reports Positive Interim Results from Phase 2a Trial of IMG-007, a Nondepleting Anti-OX40 M...
GlobeNewswire
05-06
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular isch...
GlobeNewswire
04-30
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, M...
GlobeNewswire
04-30
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the ...